Quince therapeutics provides business update and reports third quarter 2024 financial results

South san francisco, calif.--(business wire)---- $qncx #biotech--quince therapeutics, inc. (nasdaq: qncx), a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases, today provided an update on the company's development pipeline and reported financial results for the third quarter ended september 30, 2024. dirk thye, m.d., quince's chief executive officer and chief medical officer, said, “we are pleased to report accelerating enrollment of ou.
QNCX Ratings Summary
QNCX Quant Ranking